MarketVIEW: Zika virus vaccines (CAT: VAMV068)

Product Name : MarketVIEW: Zika virus vaccines
Description : Vaccine opportunity assessment
Contents : Executive presentation + commercial forecast model
Therapeutic Area : Novel viral vaccines
Publication date : February 2016
Catalogue No : VAMV068

Background

Zika virus (ZIKV) is a member of the Flaviviridae family that includes several mosquito-borne viruses of major clinical importance, including yellow fever virus, Japanese encephalitis virus and dengue virus. Although widely distributed across West and East Africa and Southeast Asia (46 countries/territories since 2007), ZIKV has only recently been identified as a major cause of disease. In most cases, ZIKV usually causes a mild and often asymptomatic illness. However, neonatal microcephaly and Guillain-Barré syndrome (GBS) have recently emerged as possible (but not definitively confirmed) complications of ZIKV infection. For example, in Brazil, an estimated 1.5 million ZIKV cases have occurred since April 2015 and up to November 2015, 1,248 neonatal microcephaly cases have been reported.

ZIKV will likely spread to other countries in the region that have Aedes mosquitoes. Autochthonous ZIKV transmission is expected to occur in the US whereby the gulf coast region and Florida are most vulnerable. The WHO declared the Zika virus outbreak a global emergency in February 2016. Many private sector companies and government-funded organizations have started work on developing a Zika vaccine due to the significant global public health concern.

The MarketVIEW product is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Zika virus vaccines across endemic (public + private) and travelers’ markets to 2035. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates for all key commercial segments. LO/BASE/HI forecast scenarios are included based upon a differing pricing justifications. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Zika virus (ZIKV) and associated sequelae e.g. ZIKV-associated microcephaly. Source materials used are literature articles, government websites, medical bodies and associations, conference proceedings etc. Previously published research by VacZine Analytics in the field of novel viral vaccines has also been utilised.

PRODUCT CONTENTS:
Published February 2016 (CAT No: VAMV068)

****This product is composed of one forecast model\(^1\) and a summary presentation\(^2\)

Title page
Contents
Author’s note
Executive summary
Commercial model: key outputs
ZIKV vaccine: predicted global revenues ($m) to 2035
ZIKV vaccine: predicted global revenues (endemic) ($m) to 2035
ZIKV vaccine: predicted global revenues (private) ($m) to 2035
ZIKV vaccine: predicted global revenues (travel) ($m) to 2035
ZIKV vaccine: price sensitivity analysis (endemic/public) - 2027
ZIKV vaccine: key model assumptions
The potential role of a ZIKV vaccine
ZIKV: comparative data to other mosquito borne viruses
ZIKV vaccine: target product profile
ZIKV vaccine: pricing considerations
ZIKV vaccine: estimating potential uptake
ZIKV: target markets for a potential vaccine
Detailed market assumptions: endemic (public)
Detailed market assumptions: endemic (private)
Detailed market assumptions: travellers (private)
Detailed market assumptions: stockpile (public)
Zika virus (ZIKV): disease background and epidemiology
The pathogen
ZIKV: transmission
ZIKV: timeline of geographical spread (1947 - 2016)
Emergence of ZIKV: Yap Island
Emergence of ZIKV: French Polynesia
Emergence of ZIKV: Brazil
Emergence of ZIKV: South (other) and Central America
ZIKV: latest transmission statistics
Countries with current or past evidence of ZIKV infections
Zika virus: economic cost in Latin America
ZIKV: clinical features

\(^1\) Model contents available upon application
\(^2\) Presentation titles may apply to more than one slide
Continued.....

ZIKV: symptoms
ZIKV: comparative symptoms with dengue virus and Chikungunya virus
ZIKV: WHO - Global Health Emergency/Strategy
ZIKV associated microcephaly
Microcephaly: latest statistics
Microcephaly rates, by state, Brazil, 2010-2014 and 2015
ZIKV & Guillain-Barré syndrome (GBS)
ZIKV: diagnosis
Algorithm for confirming ZIKV infection
Predicted distribution of Aedes aegypti
Predicted distribution of Aedes albopictus
Occurrence of Aedes albopictus in Europe and the US States
ZIKV: other routes of transmission
ZIKV: treatment and prevention
ZIKV: importation to non-endemic countries
ZIKV: autochthonous transmission in the United States
ZIKV: autochthonous transmission in the European Union
ZIKV: regions susceptible to ZIKV outbreaks
ZIKV vaccines: R&D pipeline – February 2016
Bibliography
About VacZine Analytics
Disclaimer

Slide number = 65
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- FULL PRODUCT - USD $9995.00/ GBP £7000.00*(Region license)*

* Indicative company rate only. Prevailing rate applied to date of transaction.
* A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total
Consultancy rates (commercial use) are available upon request

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.
BIBLIOGRAPHY

1. WHO. 10 facts on malaria. Available at: http://www.who.int/features/factfiles/malaria/en/
2. CDC. Dengue epidemiology. Available at: http://www.cdc.gov/dengue/epidemiology/
4. WHO. Yellow fever. Available at: http://www.who.int/mediacentre/factsheets/fs100/en/
9. PAHO. Revolving Fund Prices. Available at: http://www.paho.org/
30. HCUOmet. Available at: http://hcupnetahrq.gov/
TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009